In addition to regulating HHT resistance, MAP4K1 functions as a stand-alone prognostic indicator for AML.[34] Collectively, the research results demonstrated that MAP4K1 modulates AML progression and drug resistance through MAPK and DNA damage/repair pathways (Fig. 1B). The gene discussed is MAP4K1; the disease is acute myeloid leukemia.